TiffanyPerez(Perez)AveryMD

Oncology • Clemmons, NC

Breast Cancer, Hematologic Oncology

Medical Oncology

Join to view full profile

Dr. Avery is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Avery's full profile

Already have an account?

Office
2311 Lewisville Clemmons Rd
Clemmons, NC 27012
Phone+1 336-716-2255

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
Albert Einstein Healthcare NetworkResidency, Internal Medicine, 2003 - 2007
Louisiana State University School of Medicine in New OrleansClass of 2003

Certifications & Licensure

AR State Medical License 2022 - 2025
KY State Medical License 2021 - 2025
MN State Medical License 2021 - 2025
NC State Medical License 2015 - 2025
MD State Medical License 2022 - 2024
VA State Medical License 2022 - 2024
PA State Medical License 2003 - 2016
TX State Medical License 2008 - 2012
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2011-2012

Clinical Trials

Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer Start of enrollment: 2011 Dec 01
Unknown status
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax Start of enrollment: 2013 May 21
Completed
Phase 2
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer Start of enrollment: 2013 Apr 25
Completed
Phase 2
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer Start of enrollment: 2014 Apr 01
Terminated
Phase 1, Phase 2
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC) Start of enrollment: 2012 Feb 27
Completed
Phase 1
Subharmonic Imaging and Pressure Estimation for Monitoring Neoadjuvant Chemotherapy Start of enrollment: 2014 Mar 01
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

5 citations
Cardiovascular Assessment Tool for Breast Cancer Survivors and Oncology Providers: Usability Study
Kathryn E. Weaver, Heidi D. Klepin, Brian J. Wells, Emily V. Dressler, Karen M. Winkfield
JMIR Cancer. 2021-01-21
7 citations
Potential prognostic markers for survival and neurologic death in patients with breast cancer brain metastases who receive upfront SRS alone.
R.F. Shenker, R.T. Hughes, Emory R. McTyre, C.M. Lanier, Hui-Wen Lo
Journal of Radiosurgery and SBRT. 2018-01-01
40 citations
Monitoring Neoadjuvant Chemotherapy for Breast Cancer by Using Three-dimensional Subharmonic Aided Pressure Estimation and Imaging with US Contrast Agents: Preliminary...
Kibo Nam, John R. Eisenbrey, Maria Stanczak, Anush Sridharan, Adam C. Berger
Radiology. 2017-05-03

Press Mentions

Technology Helps Expedite Arthritis Care and Decrease ProgressionJune 11th, 2022
Dr. Tiffany Avery of NantHealth: “Ensuring That Everyone Has Access to Healthcare Is Essential”December 25th, 2020